Navigation Links
Tax Specialty Firm McGuire Sponsel Urges Qualifying Biotech Companies to Apply for New Qualifying Therapeutic Discovery Project Credit Soon
Date:6/1/2010

INDIANAPOLIS, June 1 /PRNewswire/ -- Small- to mid-sized biotech companies can soon apply for a new tax incentive that allows them to claim a credit for 50 percent of their qualified investment in new medical technologies for tax years 2009 and 2010.

The Qualifying Therapeutic Discovery Project Credit is part of the Patient Protection and Affordable Care Act created by the Obama administration and signed into law in March. The bill states that qualified therapeutic discovery projects must involve activities that are designed to treat areas of unmet medical need. New technologies can also be designed to prevent, detect, treat and potentially cure chronic or acute diseases and conditions.

"The incentive will provide the capital these biotech companies need to further their research and development programs in hopes of creating new treatments, therapies and cures for disease," said TJ Sponsel, director at specialty tax firm McGuire Sponsel. "It is a great opportunity for qualifying companies but they have to act fast. Once the money is gone, it's gone."

Companies applying for the credit must submit applications from June 21 through July 21. The Internal Revenue Service will issue certifications by Oct. 29. Taxpayers must file a separate application for each qualified investment being pursued and qualified investments are capped at $10 million per taxpayer.

"Qualified investments include wages, supplies and lab costs, depreciable property, contractor costs and other development costs," Sponsel said. "There will be an emphasis placed on qualitative aspects of the research and experimentation focused on creating high-quality, high-paying jobs in the U.S. and advancing the country's overall competitiveness in the fields of life, biological and medical sciences."

All claims must be substantiated with supporting narratives, including a discussion of scientific rationale and evidence relied on for the project, a description of the nature of development of the project and a description of the resources, management experience and organizational capacity of the applicant. Congress has asked the treasury department to approve qualified applications within 30 days.

To learn more in-depth details and guidelines for applying for a Qualifying Therapeutic Discovery Project Credit, visit www.mcguiresponsel.com/biotech or call Sponsel at (317) 564-5002.


'/>"/>
SOURCE McGuire Sponsel
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Patient Treatment for Bipolar Disorder Varies Depending on Doctor Specialty; Well Designed Clinical Trials May Be The Answer
2. Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
3. Diplomat Specialty Pharmacy Health Services Division Achieves High Marks in Pilot Program for Chronic Kidney Disease Management
4. Diplomat Specialty Pharmacy Hires Vice President of Managed Markets
5. Diplomat Specialty Pharmacy Hires National Accounts Manager to Expand Multiple Sclerosis Program
6. Botaneco signs feasibility agreement with Croda to develop specialty crop oil formulation
7. West Pharmaceutical Services to Present at the 2008 UBS Global Specialty & Generic Pharmaceuticals Conference
8. Atrium completes the sale of its Active Ingredients and Specialty Chemicals division
9. 60 Specialty Chemical, Fine Chemical & Custom Synthesis Providers Will Exhibit at Pharma ChemOutsourcing on September 8-9 in New Jersey
10. Diplomat Specialty Pharmacy Sponsors National Managed Care Roundtable for Industry Executive Advisory Board
11. A Perfect Storm Threatens Patient Access to Specialty Medical Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... British Columbia and MENLO PARK, Calif. ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company ... today announced that it will present at the 18 ... Monday, February 8, 2016 at 10:00 a.m. EST in ... Bacha , DelMar,s president and CEO, will provide an update ...
(Date:2/4/2016)... Feb. 4, 2016  Spherix Incorporated (Nasdaq: SPEX ... and monetization of intellectual property, today provided an update ... the Northern District of Texas ... Inter Partes Re-examination ("IPR") proceedings that ... The IPR was initiated on only certain claims of ...
(Date:2/4/2016)... OXFORD, England , February 4, 2016 ... Advanced Bioscience Laboratories (ABL), Inc. --> Strasbourg, ... (ABL), Inc. --> PharmaVentures is pleased to announce ... sale of its biopharmaceutical manufacturing unit in Strasbourg, ... (ABL), Inc. --> --> ...
(Date:2/3/2016)... Pa. , Feb. 3, 2016  Discovery ... company focused on developing aerosolized KL4 surfactant therapies ... of Directors has approved an inducement award as ... Fraser , its newly appointed President and Chief ... Board,s Compensation Committee on February 1, 2016 and ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint ... that Rising Market Are you interested in ... forecasts revenues for checkpoint inhibitors. Visiongain,s report gives ... submarket, product and national level. Avoid falling ... what progress, opportunities and revenues those emerging cancer ...
(Date:2/1/2016)... 1, 2016  Today, the first day of American ... to develop a first of its kind workplace health ... Watson. In the first application of Watson ... IBM ), and Welltok will create a new offering ... cognitive analytics, delivered on Welltok,s health optimization platform. The ...
(Date:1/25/2016)... Software, the world-leading supplier of image data management solutions ... data management solution OMERO Plus for the newly established ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... analysis measures the characteristics and behavior of cells, tissues ... as health and disease, the presence or absence of ...
Breaking Biology News(10 mins):